Anti-prothrombin antibodies are associated with thrombosis in children

Thrombosis Research

Volumn 125, Issue 1, 2010, Pages 19-24

  Rask, Olof ^a   Hillarp, Andreas ^a   Berntorp, Erik ^a   Ljung, Rolf ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Autoantibodies; Children; Protein S; Prothrombin; Risk factors; Thromboembolism

Indexed keywords

PROTEIN S; PROTHROMBIN; PROTHROMBIN ANTIBODY;

ARTICLE; CARDIOVASCULAR RISK; CHILDHOOD DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HUMAN; INFECTION; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; THROMBOPHILIA; THROMBOSIS; VENOUS CIRCULATION;

ADOLESCENT; ANTIBODIES, ANTI-IDIOTYPIC; AUTOANTIBODIES; CASE-CONTROL STUDIES; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MUTATION; PREVALENCE; PROTEIN S; PROTHROMBIN; RISK FACTORS; SWEDEN; THROMBOSIS;

EID: 76449084887     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2009.02.007     Document Type: Article

References (50)

1. Rask O., Berntorp E., and Ljung R. Risk factors for venous thrombosis in Swedish children and adolescents. Acta Paediatr 94 (2005) 717-722
2. Andrew M., David M., Adams M., Ali K., Anderson R., Barnard D., et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 83 (1994) 1251-1257
3. Manco-Johnson M.J., Grabowski E.F., Hellgreen M., Kemahli A.S., Massicotte M.P., Muntean W., et al. Laboratory testing for thrombophilia in pediatric patients. On behalf of the Subcommittee for Perinatal and Pediatric Thrombosis of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis (ISTH). Thromb Haemost 88 (2002) 155-156
4. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 112 (2008) 19-27
5. Rigante D., Gaspari S., Bersani G., and Stabile A. Anti-phospholipid syndrome: clinical spectrum and therapeutical/prophylactic strategies in the pediatric population. Eur Rev Med Pharmacol Sci 12 (2008) 47-53
6. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295-306
7. D'Angelo A., Della Valle P., Crippa L., Pattarini E., Grimaldi L.M., and Vigano D'Angelo S. Brief report: autoimmune protein S deficiency in a boy with severe thromboembolic disease. N Engl J Med 328 (1993) 1753-1757
8. Josephson C., Nuss R., Jacobson L., Hacker M.R., Murphy J., Weinberg A., et al. The varicella-autoantibody syndrome. Pediatr Res 50 (2001) 345-352
9. Levin M., Eley B.S., Louis J., Cohen H., Young L., and Heyderman R.S. Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatr 127 (1995) 355-363
10. Manco-Johnson M.J., Nuss R., Key N., Moertel C., Jacobson L., Meech S., et al. Lupus anticoagulant and protein S deficiency in children with postvaricella purpura fulminans or thrombosis. J Pediatr 128 (1996) 319-323
11. Peyvandi F., Faioni E., Alessandro Moroni G., Rosti A., Leo L., and Moia M. Autoimmune protein S deficiency and deep vein thrombosis after chickenpox. Thromb Haemost 75 (1996) 212-213
12. Regnault V., Boehlen F., Ozsahin H., Wahl D., de Groot P.G., Lecompte T., et al. Anti-protein S antibodies following a varicella infection: detection, characterization and influence on thrombin generation. J Thromb Haemost 3 (2005) 1243-1249
13. van Ommen C.H., van Wijnen M., de Groot F.G., van der Horst C.M., and Peters M. Postvaricella purpura fulminans caused by acquired protein s deficiency resulting from antiprotein s antibodies: search for the epitopes. J Pediatr Hematol Oncol 24 (2002) 413-416
14. Nojima J., Kuratsune H., Suehisa E., Futsukaichi Y., Yamanishi H., Machii T., et al. Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications. Clin Chem 47 (2001) 1008-1015
15. Nojima J., Kuratsune H., Suehisa E., Kawasaki T., Machii T., Kitani T., et al. Acquired activated protein C resistance associated with anti-protein S antibody as a strong risk factor for DVT in non-SLE patients. Thromb Haemost 88 (2002) 716-722
16. Galli M., Borrelli G., Jacobsen E.M., Marfisi R.M., Finazzi G., Marchioli R., et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 110 (2007) 1178-1183
17. Borrell M., Tirado I., Mateo J., Oliver A., Santamaria A., and Fontcuberta J. IgM anti-protein S antibodies as a risk factor for venous thrombosis. Haematologica 93 (2008) 1115-1117
18. Galli M. Antiphospholipid syndrome: association between laboratory tests and clinical practice. Pathophysiol Haemost Thromb 33 (2003) 249-255
19. Bardin N., Alessi M.C., Dignat-George F., Vague I.J., Sampol J., Harle J.R., et al. Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis?. Immunobiology 212 (2007) 557-565
20. Ghirardello A., Bizzaro N., Zampieri S., Iaccarino L., Bassi N., Tozzoli R., et al. Biological and clinical relevance of anti-prothrombin antibodies. Ann N Y Acad Sci 1109 (2007) 503-510
21. Sailer T., Vormittag R., Zoghlami C., Koder S., Quehenberger P., Male C., et al. The clinical significance of anti-prothrombin antibodies for risk assessment of thromboembolism in patients with lupus anticoagulant. Thromb Res 120 (2007) 295-302
22. Mackworth-Young C.G. Antiphospholipid syndrome: multiple mechanisms. Clin Exp Immunol 136 (2004) 393-401
23. Stenflo J. A new vitamin K-dependent protein. Purification from bovine plasma and preliminary characterization. J Biol Chem 251 (1976) 355-363
24. Kuhle S., Male C., and Mitchell L. Developmental hemostasis: pro- and anticoagulant systems during childhood. Semin Thromb Hemost 29 (2003) 329-338
25. van Ommen C.H., Heijboer H., Buller H.R., Hirasing R.A., Heijmans H.S., and Peters M. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr 139 (2001) 676-681
26. Naess I.A., Christiansen S.C., Romundstad P., Cannegieter S.C., Rosendaal F.R., and Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5 (2007) 692-699
27. Male C., Chait P., Ginsberg J.S., Hanna K., Andrew M., Halton J., et al. Comparison of venography and ultrasound for the diagnosis of asymptomatic deep vein thrombosis in the upper body in children: results of the PARKAA study. Prophylactic Antithrombin Replacement in Kids with ALL treated with Asparaginase. Thromb Haemost 87 (2002) 593-598
28. Svensson P.J., Zoller B., Mattiasson I., and Dahlback B. The factor VR506Q mutation causing APC resistance is highly prevalent amongst unselected outpatients with clinically suspected deep venous thrombosis. J Intern Med 241 (1997) 379-385
29. Hillarp A., Zoller B., Svensson P.J., and Dahlback B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 78 (1997) 990-992
30. Lane D.A., Mannucci P.M., Bauer K.A., Bertina R.M., Bochkov N.P., Boulyjenkov V., et al. Inherited thrombophilia: Part 2. Thromb Haemost 76 (1996) 824-834
31. Lane D.A., Mannucci P.M., Bauer K.A., Bertina R.M., Bochkov N.P., Boulyjenkov V., et al. Inherited thrombophilia: Part 1. Thromb Haemost 76 (1996) 651-662
32. Manco-Johnson M.J., and Nuss R. Lupus anticoagulant in children with thrombosis. Am J Hematol 48 (1995) 240-243
33. Ogino S., and Wilson R.B. Genotype and haplotype distributions of MTHFR677C>T and 1298A>C single nucleotide polymorphisms: a meta-analysis. J Hum Genet 48 (2003) 1-7
34. Koch H.G., Nabel P., Junker R., Auberger K., Schobess R., Homberger A., et al. The 677T genotype of the common MTHFR thermolabile variant and fasting homocysteine in childhood venous thrombosis. Eur J Pediatr 158 Suppl 3 (1999) S113-S116
35. Weisberg I.S., Jacques P.F., Selhub J., Bostom A.G., Chen Z., Curtis Ellison R., et al. The 1298A->C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 156 (2001) 409-415
36. Kosch A., Koch H.G., Heinecke A., Kurnik K., Heller C., and Nowak-Gottl U. Increased fasting total homocysteine plasma levels as a risk factor for thromboembolism in children. Thromb Haemost 91 (2004) 308-314
37. Bjorke Monsen A.L., and Ueland P.M. Homocysteine and methylmalonic acid in diagnosis and risk assessment from infancy to adolescence. Am J Clin Nutr 78 (2003) 7-21
38. den Heijer M., Willems H.P., Blom H.J., Gerrits W.B., Cattaneo M., Eichinger S., et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 109 (2007) 139-144
39. Koster T., Blann A.D., Briet E., Vandenbroucke J.P., and Rosendaal F.R. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345 (1995) 152-155
40. Kyrle P.A., Minar E., Hirschl M., Bialonczyk C., Stain M., Schneider B., et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343 (2000) 457-462
41. Goldenberg N.A., Knapp-Clevenger R., and Manco-Johnson M.J. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 351 (2004) 1081-1088
42. Meijers J.C., Tekelenburg W.L., Bouma B.N., Bertina R.M., and Rosendaal F.R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 342 (2000) 696-701
43. Guermazi S., Regnault V., Gorgi Y., Ayed K., Lecompte T., and Dellagi K. Further evidence for the presence of anti-protein S autoantibodies in patients with systemic lupus erythematosus. Blood Coagul Fibrinolysis 11 (2000) 491-498
44. Rao L.V., Hoang A.D., and Rapaport S.I. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 88 (1996) 4173-4182
45. Zhao Y., Rumold R., Zhu M., Zhou D., Ahmed A.E., Le D.T., et al. An IgG antiprothrombin antibody enhances prothrombin binding to damaged endothelial cells and shortens plasma coagulation times. Arthritis Rheum 42 (1999) 2132-2138
46. Galli M., Willems G.M., Rosing J., Janssen R.M., Govers-Riemslag J.W., Comfurius P., et al. Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C. Br J Haematol 129 (2005) 240-247
47. Astermark J., Oldenburg J., Carlson J., Pavlova A., Kavakli K., Berntorp E., et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 108 (2006) 3739-3745
48. Astermark J., Oldenburg J., Pavlova A., Berntorp E., and Lefvert A.K. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 107 (2006) 3167-3172
49. Astermark J., Wang X., Oldenburg J., Berntorp E., and Lefvert A.K. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 5 (2007) 263-265
50. Pavlova A., Diaz-Lacava A., Zeitler H., Satoguina J., Niemann B., Krause M., et al. Increased frequency of the CTLA-4 49 A/G polymorphism in patients with acquired haemophilia A compared to healthy controls. Haemophilia 14 (2008) 355-360